Full Press Release Details
>Listen on Spotify>Listen on Apple Products>Listen on Amazon Music>Listen on iHeart
Johnson & Johnsonkicked off Q3 earnings seasonon Tuesday with the announcement that it is splitting its orthopedics and medtech operations and that it has yet to reach a drug pricing deal with the White House, though CEO Joaquin Duato did say those discussions are ongoing.
In advance of its Nov. 5 earnings call, Novo Nordisk, under the direction of new CEO Maziar Mike Doustdar, has been busy making moves, doubling down on MASH last week with its$5.2 billion buy of Akero. Then this week, Novo became the latest company tocut cell therapy, following Takeda’s recent exit from the space.
Meanwhile, as the government shutdown continues, so too does thechaos at the CDC, where more than 1,000 employees received termination notices last Friday—only for hundreds to be told never mind. At the FDA, however, there is some consistency despite the overhaul, with the agency on track for anaverage number of approvalsthis year. And a recent report onbreakthrough designationsshows that the regulatory award often leads to an FDA greenlight.
On the legislative front, theBIOSECURE Actis back, as a slimmed down version passed the Senate last week as part of the defense spending bill. The latest version of BIOSECURE, which is meant to distance American biopharma from Chinese collaborators, doesn’t name specific companies as previous iterations did and must still gain the Senate’s support.